|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tumor xenografts were implanted in nude mice to verify the effect of CDA silencing on tumor growth in vivo.
|
30002603 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The purpose of this study was to determine whether CDA deficiency could be associated with tumors from the general population and could constitute a predictive marker of susceptibility to antitumor drugs.<b>Experimental Design:</b> We analyzed <i>CDA</i> expression <i>in silico</i>, in large datasets for cancer cell lines and tumors and in various cancer cell lines and primary tumor tissues using IHC, PDXs, qRT-PCR, and Western blotting.
|
27601591 |
2017 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
After the results were adjusted for clinical predictors, the variant allele of rs1048977 in the CDA gene was associated with tumor response in a dominant model (OR, 0.23; 95% CI, 0.06-0.93; p = 0.039).
|
26418006 |
2015 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This pilot study strongly suggests that UM patients are nearly five-times more likely to have progressive disease than patients with normal or low CDA activities, and that beside molecular events at the tumor level, upstream deregulations affecting drug disposition should be taken into account.
|
23837479 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
It is metabolized first in the liver by carboxylesterases to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR), which is subsequently converted to 5'-deoxy-5-fluorouridine ribose (5'-DFUR) by cytidine deaminase in tumour and normal tissues.
|
21915635 |
2012 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
The CDA A-76C, dCK C-1205T, RRM1 A33G, and hENT1 C913T genotypes were significantly associated with grade 3 to 4 neutropenia (P = .020, .015, .003, and .017, respectively).The CDA A-76C and hENT1 A-201G genotypes were significantly associated with tumor response to therapy (P = .017 and P = .019).
|
20665488 |
2010 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The role of drug transport and metabolism on gemcitabine cytotoxicity was examined with specific inhibitors, whereas transcription analysis of human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), 5'-nucleotidase (5'-NT), cytidine deaminase (CDA), and ribonucleotide reductase subunits M1 and M2 (RRM1 and RRM2) was done by quantitative reverse transcription-PCR in tumor tissue isolated by laser microdissection from surgical or biopsy samples of 102 patients.
|
16585222 |
2006 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Activities of dCK and CDA were measured in a panel of eight gemcitabine-sensitive and -resistant tumors of a different origin (pancreas, lung, colon, ovary, and head and neck) grown as s.c. tumors in mice.
|
12477049 |
2002 |
|
Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
This observation may be exploited for the treatment of neuroblastoma patients having a tumour with a chromosome Ip deletion including the domain containing the gene encoding cytidine deaminase.
|
9066694 |
1997 |